AUSTIN, Texas, Oct. 8, 2012 /PRNewswire/ -- Luminex
Corporation (Nasdaq: LMNX) today announced that it expects to
report results for the third quarter of 2012 on Monday, October 29, 2012. A press release
announcing the results is scheduled for release after the close of
trading.
(Logo:
http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
Management will hold a conference call to discuss the operating
highlights and financial results for the third quarter and nine
months ended September 30, 2012 on
October 29, 2012, at 5:00 p.m. Eastern time.
The conference call will be webcast live and will be accompanied
by a slide presentation, both of which may be accessed at Luminex
Corporation's website at http://www.luminexcorp.com. Simply log on
to the website, go to the About Us section and access the Investor
Relations link. Please go to the website at least 15 minutes prior
to the call to register, download and install any necessary
audio/video software. If you are unable to participate during the
live webcast, the call and slides will be archived for six months
on the website using the 'replay' link.
The use of pop-up blocking software may impair your ability to
view webcasts. If you use this software, press and hold the CTRL
key when you click on the Register button. Please contact your IT
group if you are unable to override this feature. Unauthorized
recording or downloading of this event is not permitted.
About Luminex Corporation
Luminex is committed to applying its passion for innovation
toward advancing healthcare and research worldwide. The Company is
transforming global healthcare and life-science research through
the development, manufacturing and marketing of proprietary
instruments and assays utilizing xMAP®
open-architecture, multi-analyte platform and MultiCode®
real-time polymerase chain reaction (PCR) and multiplex PCR-based
technologies, that deliver cost-effective and rapid results to
clinicians and researchers. Luminex's technology is commercially
available worldwide and in use in leading clinical laboratories as
well as major pharmaceutical, diagnostic, biotechnology and
life-science companies. The Company is meeting the needs of
customers in markets as diverse as clinical diagnostics,
pharmaceutical drug discovery, biomedical research including
genomic and proteomic research, personalized medicine, bio-defense
research and food safety. For further information on Luminex
Corporation and the latest advances in multiplexing using award
winning technology, please visit http://www.luminexcorp.com.
Statements made in this release that express Luminex
Corporation's or management's intentions, plans, beliefs,
expectations or predictions of future events are forward-looking
statements. The words "believe," "expect," "intend," "estimate,"
"anticipate," "will," "could," "should" and similar expressions are
intended to further identify such forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995.
It is important to note that the Company's actual results or
performance could differ materially from those anticipated or
projected in such forward-looking statements. Factors that could
cause Luminex's actual results or performance to differ materially
include risks and uncertainties relating to, among others, market
demand and acceptance of Luminex's products, the Company's
dependence on strategic partners for development, commercialization
and distribution of products, concentration of the Company's
revenue in a limited number of strategic partners, fluctuations in
quarterly results due to a lengthy and unpredictable sales cycle
and bulk purchases of consumables, Luminex's ability to scale
manufacturing operations and manage operating expenses, gross
margins and inventory levels, potential shortages of components,
competition, the timing of regulatory approvals, the
implementation, including any modification, of the Company's
strategic operating plans, risks and uncertainties associated with
implementing our acquisition strategy and the ability to integrate
acquired companies or selected assets into our consolidated
business operations, as well as the risks discussed under the
heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q,
as filed with the Securities and Exchange Commission. The
forward-looking statements contained herein represent the judgment
of Luminex as of the date of this press release, and Luminex
expressly disclaims any intent, obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements to reflect any change in Luminex's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based.
Luminex Corporate Contact:
Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com
Luminex Investor Relations Contact:
Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com
SOURCE Luminex Corporation